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of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with lung cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for lung cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁgure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂecting ranges of 261 KRW∼286 KRW and 3414 KRW∼4538 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married and younger respondents, with higher income and education have more 
MWTP compared to their respective counterparts. One interesting point is that depen-
dents’ MWTP of survival rate is higher than that of insurance premium payers 
although MTWP of total treatment costs for dependents is signiﬁcantly lower than 
premium payers’ MWTP.
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OBJECTIVES: This study, using DCE method, ﬁgures out the characteristics of the 
decision-making for liver cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for liver cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with liver cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for liver cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁgure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂecting ranges of 212 KRW∼294 KRW and 3458 KRW∼4777 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married respondents, with higher education have more MWTP compared to their 
respective counterparts. One interesting point is that MWTP of high income group is 
lower than that of low income counterparts. This might be related to a lower alcohol 
consumption of high incomers who are less prone to liver cancer compared to low 
incomers.
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OBJECTIVES: Human Papilloma Virus (HPV) is a sexually transmitted disease (STD) 
and is the leading cause of cervical cancer. Merck’s Gardasil, an HPV vaccine in the 
US, protects against cervical cancer and genital warts. The CDC recommends HPV 
vaccination for females 11–12 years old, yet vaccination rates vary signiﬁcantly by 
state from 15.8% to 54.7%. The objective of this study was to evaluate coverage of 
HPV vaccination and explore explanation for variation across the United States. 
METHODS: Our study included analysis of CDC vaccination rates, American Com-
munity Survey (Census) data, and additional government agency datasets. The vac-
cination rate is deﬁned as vaccination of the 1st dose (three doses are recommended 
in total). Health care system and socioeconomic characteristics were identiﬁed and 
evaluated with respect to HPV vaccine coverage. Regression models were run on each 
state-level variable separately. RESULTS: The correlation between HPV vaccine rates 
and the percent of children attending religious service on a weekly basis resulted in a 
signiﬁcant inverse relationship. The analysis yielded a R2 value of 0.41, an f-value of 
33.47 and a −5.79 t Stat score. Teen birth rates also resulted in a negative correlation 
with a R2 value of 0.18, an f-value of 10.78 and a −3.28 t Stat score. Pediatricians 
per 1000 state inhabitants and percent of people who completed a bachelor’s degree 
yielded positive correlation to vaccination rates with R2 values of 0.18 and 0.16, 
respectively. Factors that did not correlate to vaccination rates included cervical cancer 
rates, STD rates, abortion rates, and high school graduation rates. CONCLUSIONS: 
An array of socio-economic and health care system variables were correlated with the 
HPV vaccination rates by state. Public health programs focused on inﬂuencing these 
state-level variables may precipitate improvement in HPV coverage.
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OBJECTIVES: To determine prevalence and correlates of Human Papillomavirus 
(HPV) vaccination in adolescent girls who were recommended to receive vaccine by 
their health care providers. METHODS: A retrospective cross-sectional analysis 
involving adolescent girls (11–17 years) was conducted using the 2007 National 
Survey of Children’s Health (NSCH). The analysis focused on adolescent girls who 
were recommended to receive HPV vaccine. Descriptive weighted statistics was used 
to examine prevalence of HPV vaccination. Multivariate logistic regression within 
the conceptual framework of Andersen Behavioral Model was used to examine the 
correlates of HPV vaccination in this at-risk population. RESULTS: Of 14.43 million 
adolescent girls in the United States, 3.69 million or 25.54 % (95% Conﬁdence 
Interval [CI], 24.02–27.06) were recommended to receive the HPV vaccine by their 
health care provider. Amongst those who were recommended, only 48.75% (95% 
CI, 45.37–52.13) received the HPV vaccine. The majority who received the HPV 
vaccine were in the 13–17 age groups (82.67%), white (66.94%), and non-Hispanic 
(84.83%). Multivariate logistic regression revealed that enabling (socioeconomic 
status) and predisposing (number of adults in the household and preventive medical 
care visit) factors were signiﬁcantly associated with the HPV vaccination. Children 
living at 100–200% of the Federal Poverty Level (FPL) (Odds Ratio [OR] 0.54, 
95% CI 0.30–0.98) were less likely to receive the vaccine than those living below 
100% of the FPL. Children in households with two or more adults (OR 0.51, 95% 
CI, 0.33–0.80) were negatively associated and those with any previous preventive 
medical care visit (OR 2.28, 95% CI, 1.36–3.84) were positively associated with 
HPV vaccination. CONCLUSIONS: Less than half of the girls received HPV vaccine 
among those who were recommended by their health care provider. The study ﬁnding 
emphasizes importance of predisposing and enabling factors for HPV vaccination. 
Policy and educational efforts can focus on these factors to improve HPV vaccination 
rates.
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IDEAL VIAL SIZE FOR BORTEZOMIB: REAL WORLD DATA ON WASTE 
AND COST REDUCTION IN MULTIPLE MYELOMA (MM)
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OBJECTIVES: Single size vials of chemotherapy drugs may be a source of waste and 
increase in treatment costs. Bortezomib, a drug frequently used in MM treatments, is 
available in a 3.5mg vial (above the average dose commonly prescribed) without 
antimicrobial preservatives, making mandatory its administration within 8 hours of 
preparation. Through real world data collected from Evidencias® a dedicated data-
base of cancer treatments (www.evidencias.com.br) we aimed to demonstrate which 
would be the optimal vial presentation for Bortezomib. METHODS: From November 
2007 to October 2009 all patients with MM treated with Bortezomib were identiﬁed 
on Evidencias®. Analysis of prescribed, dispensed and wasted doses, their costs and 
which would be the ideal vial size were performed. RESULTS: We identiﬁed 35 
patients that received Bortezomib in this period (mean body surface area of 1.73 m2). 
Mean prescribed dose per infusion was 2.1 mg which generated a waste of 1.4 mg 
(40%) of each vial. Due to this waste, the total amount of the drug used was 1 
907.6 mg at a cost of US$1 192,849.98 to cover the prescribed amount of 1,216.14 mg 
(US$727,923.08). The total waste was of 691.36 mg (US$464,926.89). The patients 
received a total of 131 cycles (mean of 3.77). The mean waste was 4.89 mg per cycle 
and 14.4 mg per patient. If a 3 mg vial were available, (maintaining a proportional 
price to the 3.5 mg one) the total cost of treatment would be US$994,836.88 (16.6% 
lower) and the drug waste would be reduced by 34.72% (9.4 mg per patient). CON-
CLUSIONS: A simple adjustment in vial size reduces Bortezomib waste by 34.72% 
and results in a cost reduction of 16.6%. Further models using different vial sizes, 
combined to dose adjustment and patient scheduling may increase the economy even 
more.
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OBJECTIVES: Docetaxel (D) is well recognized as the ﬁrst-line chemotherapy in 
patients with metastatic prostate cancer (PC). Of interest is the relationship between 
the number of treatment cycles and overall survival (OS) beneﬁt. This study investi-
gated the relationship between number of cycles and OS in a community practice. 
METHODS: The Georgia Cancer Specialist Database (2003–2008) was used. Patients 
with initial stage IV PC receiving D were followed from the date of ﬁrst D use to the 
earlier of death or loss to follow-up. The three-month period prior to the ﬁrst D use 
was the baseline. Patients were stratiﬁed into <10 vs. ≥10 groups based on mean cycle 
number. OS was compared using the Kaplan-Meier curve. The impact of cycle number 
on OS was further examined using multivariate Cox model with adjustment of age, 
comorbidity, baseline PSA, baseline bisphosphonate use, hormonal therapies and other 
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chemotherapy during the follow-up. Sensitivity analyses (SA) with cycle number 
controlled as a count variable and a dummy variable (with different thresholds at 6, 
7, 8, 9) were performed to test the robustness of the association. RESULTS: The 
sample included 47 patients, with mean age 75 (ranging 58–95), average baseline PSA 
296 ng/ml (ranging 0.21–2139). The average number of treatment cycles were 10 
(ranging 1–52), with 27 (57.5%) completing <10 and 19 (42.5%) patients ≥10 cycles. 
Median survival was 224 days for <10 group, and 570 days for ≥10 group (P = 
0.0011). The Cox model found a higher likelihood of survival for ≥10 group (HR = 
0.33, P = 0.0117). Consistent results were found in SA. CONCLUSIONS: This study 
suggested that more treatment cycles of D was associated with prolonged OS for 
metastatic PC. The results could be confounded by unadjusted factors, therefore, no 
cause inference can be drawn based on this analysis.
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OBJECTIVES: To examine: 1) formulary coverage for colorectal cancer drugs by 
different hospitals in Taiwan’s National Health Insurance(NHI); 2) how coverage 
varies by hospital level (medical center vs. regional hospital) and location; and 3) how 
coverage varies by drug characterist. METHODS: Nationwide cross-sectional survey 
of regional hospitals and medical centers in Taiwan during June to August, 2009. A 
validated and structured questionnaire was used as the research instrument. The 
outcome variables were formulary coverage, cost sharing tier, and utilization manage-
ment tools (prior authorization, quantity limit, step therapy) for the drugs covered by 
insurance beneﬁt or self-payment. We examined whether there was an association 
between hospital type (level, ownership and location) and drug characteristics (drug, 
costs, and years since approval) with these outcomes. RESULTS: A total of 95 hospi-
tals having oncology department constituted the study group, with respond rate of 
90.5% (86/95). For eight colorectal cancer drugs, the coverage rate ranged from 
98.8% to 74.4% (leucovorin 95.3%; ﬂuorouracil 98.8%; oxaliplatin 95.3%; irinote-
can 88.4%; tegafur-uracil 95.3%; capecitabine 87.2%; cetuximab 74.4%; bevaci-
zumab 79.1%). Capecitabine, cetuximab and bevacizumab are all original brand 
drugs; on the contrary, ﬂuorouracil and tegafur-uracil are all generic sources. Cetux-
imab and bevacizumab have a lower proportion of being regularly prepared (68.8% 
and 76.5%, respectively), comparing to other six drugs with higher proportion than 
85%. Besides the NHI reimbursement guidance, the proportion of having an in-hos-
pital mandated rule was higher for cetuximab and bevacizumab (21.9% and 23.9%, 
respectively). Regardless of differences in hospital level, ownership or locations, the 
two most important factors inﬂuencing the decision making of formulary listing was 
the safety and effectiveness of the drug. CONCLUSIONS: Comparing to target therapy 
drugs, cetuximab and bevacizumab, patients had less accessibility barriers to tradi-
tional colorectal cancer drugs. Furthermore, the geographic differences have an impact 
on accessibility of such drugs by patients.
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OBJECTIVES: Although chemotherapy was proven efﬁcacious for metastatic breast 
cancer (MBC) in clinical trials, lower chemotherapy rates have been observed among 
older patients. This may be due to greater uncertainty in the trade-off between the 
risks and the beneﬁt of chemotherapy associated with older age because of the under-
representation of older patients in cancer clinical trials. These uncertainties may cause 
other non-clinical factors, such as access, to matter more for older patients. We 
examined the effect of access to cancer care, including travel distance to the nearest 
oncologist practice, local area per capita number of oncologists, per capita number of 
hospices, and area chemotherapy rate among stage IV cancer patients across four 
cancers, on age-related difference in chemotherapy use for elderly MBC patients. 
METHODS: The retrospective cohort study used the 1992–2002 SEER-Medicare 
database. Chemotherapy use was deﬁned as at least one chemotherapy-related claim 
within 6 months post diagnosis. We deﬁned ﬁve age subgroups: 66–69, 70–74, 75–79, 
80–84, and 85+. For each age subgroup, we used multivariate logistic regression to 
estimate the effect of access to cancer care on chemotherapy use controlling for covari-
ates. RESULTS: Among 4533 elderly patients with MBC, 30.16% used chemotherapy. 
Chemotherapy rate decreased with age. Subgroup analysis showed that the area treat-
ment rate was positively associated with chemotherapy use in all age groups. In 
addition, among patients who were 85+ years old, local area oncologist supply was 
negatively associated with chemotherapy use. This effect was not observed among 
younger age groups. CONCLUSIONS: Access to cancer care affects chemotherapy 
choice among older patients whose clinical evidence is unclear, which may be attribut-
able to patient preferences and physician concerns of real beneﬁts of chemotherapy 
considering older patients’ limited life expectancy and higher risk of toxicities. The 
more uncertain the evidence with age, the more access may affect chemotherapy 
choice.
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OBJECTIVES: The purpose of this review is to evaluate the published literature to 
assess social inequalities in lung cancer using the ‘cancer disparities grid.’ METHODS: 
Three computerized databases were searched from January 1990 to December 2009 
to identify published English language articles that collected data from study partici-
pants living in the United States. Abstracts were reviewed and articles that dealt with 
social inequality and lung cancer were selected. A total of 96 articles were identiﬁed 
that met the selection criteria. These articles were then classiﬁed into the appropriate 
cell of the cancer disparities grid. RESULTS: The majority of research identiﬁed for 
the grid has focused primarily in domain of inequality, race/ethnicity and racism, and 
one column of the cancer continuum, cancer treatment. About one-third of the articles 
focused on multiple aspects of social inequalities. There were few or no published 
research articles within many of the domains of social inequality along the continuum 
of lung cancer prevention, treatment, and outcomes. CONCLUSIONS: This review 
found only a modest amount of research has been conducted that has examined the 
inﬂuence of social inequalities on lung cancer. Findings suggest that a multidisciplinary 
approach is needed to measure and remedy these social inequalities.
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OBJECTIVES: Disparity in breast cancer treatment is a serious concern in the elderly 
since majority of the breast cancer cases occur in elderly women aged 65 and above. 
We examined racial disparities associated with breast cancer treatment and survival 
in elderly patients with early stage operable breast cancer. METHODS: We studied a 
cohort of 23,110 node positive and 31,572 node negative women aged 65 and over 
diagnosed with incident American Joint Committee on Cancer (AJCC) stage I, II or 
IIIa (early stage operable) breast cancer between January 1, 1991 and December 31, 
2002 using SEER-Medicare data. Multivariate logistic regression analyses were per-
formed to assess the relative odds of receiving surgery (Breast Conserving Surgery, 
BCS versus Mastectomy), chemotherapy (within 6 months of diagnosis) and radiation 
after BCS for African Americans compared to Whites. Cox proportional hazard ratio 
of mortality was used to determine the effectiveness of surgery, chemotherapy and 
radiation after BCS for African Americans compared to Whites after adjustment for 
patient and tumor characteristics. RESULTS: Of the total 54,682 women with breast 
cancer 93.7% were Whites and 6.3% were African Americans. There was a signiﬁcant 
difference between African American and White women in receiving BCS and radia-
tion after BCS; however this difference was explained by patient demographics, tumor 
characteristics and socioeconomic status (SES). Multivariate analysis indicated that 
African American women with node positive and node negative tumors were 21% 
(OR, 0.79; CI, 0.68–0.92) and 19% (OR, 0.81; CI, 0.68–0.97) less likely than White 
women to receive adjuvant chemotherapy. There was no signiﬁcant difference in 
mortality between African American and White women in similarly treated groups. 
CONCLUSIONS: Underutilization of systemic adjuvant chemotherapy in African 
American women requires attention and may serve as potential areas for appropriate 
intervention. Access to quality adjuvant treatments may eliminate observed racial 
differences in outcomes.
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OBJECTIVES: Lung cancer is the most deadly cancer among other types of cancer, 
in both men and women. In 2005, lung cancer accounted for more deaths then breast 
cancer, prostate cancer and colon cancer combined. The purpose of this study was to 
describe the average annual medical resource use and costs incurred by individuals 
with lung cancer in the United States civilian noninstitutionalized population.
METHODS: Data for this study were derived from the 2002–2007 Medical Expen-
diture Panel Survey. Individuals with lung cancer diagnosis were identiﬁed by using 
truncated International Classiﬁcation of Diseases (Ninth Revision) codes obtained 
from household interviews. All individuals >40 years old with health care resource 
use or expenditures for lung cancer were included in this study. Estimates were 
weighted to reﬂect the complex sampling scheme. A societal perspective was adopted 
for this analysis. RESULTS: The average annual mean total health care expenditures 
among individuals with lung cancer were $23,249 (2007 US dollars). Approximately 
34% of average annual direct medical expenditures in individuals with lung cancer 
were for inpatient hospitalization. Annually, lung cancer patients had on average 17 
ofﬁce based provider visits to physician and non-physicians resulting in $5,763 as 
expenses. Further, lung cancer patients had on average 6 outpatient visits annually, 
resulting in $4,304 as expenses. CONCLUSIONS: Lung Cancer causes a large societal 
burden of illness that is expected to increase. This study provides a valuable founda-
tion and historical measure against which to compare other estimates.
